Enanta Pharmaceuticals (ENTA) to Release Earnings on Wednesday

Enanta Pharmaceuticals (NASDAQ:ENTA) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Enanta Pharmaceuticals to post earnings of ($1.16) per share and revenue of $17.25 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. During the same period last year, the business posted ($1.33) EPS. The company’s revenue was down 22.8% on a year-over-year basis. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock opened at $5.17 on Tuesday. Enanta Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $17.80. The stock has a 50 day moving average price of $6.31 and a two-hundred day moving average price of $10.02. The stock has a market capitalization of $110.28 million, a PE ratio of -0.94 and a beta of 0.54.

Analysts Set New Price Targets

A number of equities research analysts have commented on ENTA shares. HC Wainwright reduced their price objective on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Finally, Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.89% of the stock is currently owned by corporate insiders.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.